With each cancer patient responding differently to treatment therapy, Intermountain ICG100™ tests offers a unique process of analyzing the genetic makeup of each individual patient. A team of skilled specialists review each test with the objective of preparing the most effective customised, targeted treatment plan for each patient.
Where standard therapies fail, precision medicine offers hope for late stage cancer.
Why Intermountain ICG100™?
Personalised cancer treatment.
Offers a targeted cancer panel that detects 162 genomic alterations.
A molecular tumor board made up of a panel of expert scientists and physicians who recommend individual, effective treatment options.
Who is the test for?
For patients diagnosed with stage IV cancer. Method approved for late-stage cancer patients who have failed a traditional treatment method.
How long does it take to get the results?
More information for clinicians
|SNPs||Insertions||Deletions||Copy Number Alterations|
|Mean depth of coverage||>300×|
|Turn-around time||<14 days for molecular tumor board report|
The ICG100™ tests 162 genes that are associated in cancer pathways.
|ICG100™ Gene List|
Concordance of clinical significant variant detected by external NGS reference laboratory with ICG100™ panel are available upon request.
|Intermountain Precision Genomics|
|Number of Genes||162 genes|
|Technology||Whole Exon Sequencing of 162 cancer related genes.|
ICG100-2.0™ (was NGS to identify individual mutations within a person’s cancer cells to identify specific DNA targets for personalised drug treatment.)
DNA sequencing for 162 cancer-related genes. Test detects all classes of genomic alteration:
|Performance||SNP Sensitivity 98.83%|
|Mean Depth of Coverage||>300×|
|% of tests with actionable mutations detected||>80%|
|No. of Regions Sequenced||1300|
|Molecular Tumor Board?||Yes|
|Types of therapy reported||Targeted therapies, immuno-therapies, clinical trials.|
|Application||For patients diagnosed with late stage cancer. Method approved for late-stage cancer patients who have failed a traditional treatment method.|
|Lab accreditation||CAP accredited|
|Follow-up recommendations||With the Molecular Tumour Board review of patients, specific recommendations as to what drugs to use to target that specific mutations can be made. Including oral medications that don’t have all the side effects of traditional therapies.|
|Recent updates||Intermountain healthcare leaders are seeing promising results from the more personalised treatments for late-stage cancer patients due to the advancements in genomics diagnostic technology.|